BiotechTubeBiotechTube
Home/Prelude Therapeutics/John H. Lee, M.D., Ph.D.
JH

John H. Lee, M.D., Ph.D.

Director

Prelude Therapeutics

Therapeutic Areas

Oncology

Prelude Therapeutics Pipeline

DrugIndicationPhase
PRT3789SMARCA4-deficient tumors (e.g., NSCLC, other solid tumors)Phase 1/2
PRT2527Hematologic malignancies (CLL, NHL) and solid tumorsPhase 1
PRT3645Advanced or metastatic solid tumorsPhase 1
PRT7732Advanced solid tumors and hematologic malignanciesPreclinical

Leadership Team at Prelude Therapeutics

KV
Krishna Vaddi, Ph.D.
Chief Executive Officer, President, and Founder
DJ
David J. Wurzer
Chief Financial Officer and Treasurer
DB
David B. Roth, M.D., Ph.D.
Chief Medical Officer
DB
David B. Donabedian, Ph.D.
Chief Scientific Officer
PM
Paul M. McBarron
Chief Operating Officer
MD
Martin D. Williams
Chairman of the Board of Directors
JE
John E. Goddard, Ph.D.
Director
JT
John T. Greene
Director
LB
Laurie B. Keating
Director
View full Prelude Therapeutics profile